Dr. Richard Cheng and Dr. C. Michael Gibson discuss: Presentation, screening, and disease progression of variant ATTR-CM June 4, 2025 Uncategorized Disclosures: Sponsored by BridgeBio Pharma, Inc Article Navigation Dr. Kevin Alexander and Dr. C. Michael Gibson discuss datapresented at ACC 2025: Dr. Kevin Alexander, Acoramidis Improves Serum TTR Levels in Patients with Wild-Type or Variant Transthyretin Amyloid Cardiomyopathy sponsored byBridgeBio Pharma, Inc. Dr. Ron Witteles and Dr. C. Michael Gibson discuss: Atrial fibrillation, arrythmias, and other cardiac manifestations in patients with ATTR-CM
